Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.

Blood - 15 Nov 2012

Pamba Allan, Richardson Naomi D, Carter Nick, Duparc Stephan, Premji Zul, Tiono Alfred B, Luzzatto Lucio

Abstract excerpt

Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygou...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Hemolytic
Share to Blood Transfusion
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dapsone

Share to Glucosephosphate Dehydrogenase Deficiency

Share to Multicenter Studies as Topic

Share to Proguanil

Share to Single-Blind Method

Source

Identifiers

PMID: 22993389
DOI: 10.1182/blood-2012-03-416032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22993389-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.PMID 22993389Read ↗

Glucose-6-phosphate dehydrogenase deficiencySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.Semantic proximity Read ↗

G6PD deficiency: global distribution, genetic variants and primaquine therapy.Semantic proximity Read ↗

Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.Semantic proximity Read ↗

Updated Worldwide Epidemiology of Inherited Erythrocyte DisordersSemantic proximity Read ↗

Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.Semantic proximity Read ↗

G6<scp>PD</scp> deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsSemantic proximity Read ↗

Hematological and molecular analysis of patients with G6PD deficiency revealed coexistent hereditary spherocytosis and alpha thalassemia.Semantic proximity Read ↗

The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects.Semantic proximity Read ↗

Hematological parameters and red blood cell morphological abnormality of Glucose-6-Phosphate dehydrogenase deficiency co-inherited with thalassemiaSemantic proximity Read ↗

[Glucose-6-phosphate dehydrogenase deficiency and hereditary hemolytic anemia].Semantic proximity Read ↗

Integrated Phenotypic and Genotypic Approaches for Accurate Diagnosis of G6PD Deficiency: Implications for Drug Safety in ThailandSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.